Union Bancaire Privee, UBP SA
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 1716607
GENEVA 1, V8
Position in REGN
as of Jun 30, 2026
· filed Jul 16, 2026
Position Value
$356,041
-$3,023,486 QoQ
Shares Held
571
-86.9% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#220
of 406 holders
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 95%
Shared 0%
None 5%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Derivatives in REGN
reported options exposure · as of Jun 30, 2025CallValue
$0
CallShares
0
PutValue
$2,625
PutShares
5
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Union Bancaire Privee, UBP SA holds $2,062,233 across 7 Biotechnology names. REGN ranks #2 (17.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRNA |
Moderna, Inc.
|
15,200 | $1,064,456 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
This page
|
571 | $356,041 | |
| 3 | AUPH |
Aurinia Pharmaceuticals Inc.
|
13,000 | $220,610 | |
| 4 | OCUL |
Ocular Therapeutix, Inc
|
20,000 | $196,400 | |
| 5 | ABVX |
Abivax S.A.
|
1,100 | $146,586 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
|
880 | $78,126 | |
| 7 | TENX |
Tenax Therapeutics, Inc.
|
1 | $14 |
All Filings in REGN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $356,041 | 571 | Shares | Defined | 2026-07-16 | |
| 2026-03-31 | $3,379,527 | 4,374 | Shares | Defined | 2026-04-22 | |
| 2025-12-31 | $3,082,076 | 3,993 | Shares | Defined | 2026-01-05 | |
| 2025-09-30 | $290,693 | 517 | Shares | Defined | 2025-10-07 | |
| 2025-06-30 | $2,625 | 5 | Put | Defined | 2025-07-18 | |
| 2024-12-31 | $3,561 | 5 | Shares | Defined | 2025-02-04 | |
| No filing history on record for this holder in this stock. | ||||||